Abstract
ABCB1 (P-glycoprotein) is an efflux transporter that limits the cellular uptake levels of various drugs in intestine, brain, and other tissues. The expression of human ABCB1 has recently been reported to be under the control of nuclear receptor NR1I subfamily members, pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3). Here, we have investigated the involvement of another NR1I member, vitamin D receptor (VDR, NR1I1), in ABCB1 expression. In the human colorectal adenocarcinoma cell line LS174T, which abundantly expresses VDR, both 1α,25-dihydroxyvitamin D3 (1,25-VD3) and lithocholic acid (LCA) increased ABCB1 mRNA levels. Reporter gene assays in LS174T cells with constructs containing various lengths of the ABCB1 regulatory region revealed that the region containing multiple nuclear receptor binding motifs located at –7.8 kilobases [termed nuclear receptor-responsive module (NURREM)], to which PXR and CAR also bind, is essential for the VDR-mediated ABCB1 transactivation. Further reporter assays with constructs containing truncated NURREM and gel shift assays suggested simultaneous binding of multiple VDR/retinoid X receptor α heterodimers to NURREM. Furthermore, knockdown of VDR expression in LS174T cells blocked the LCA- and the 1,25-VD3-induced transcription of ABCB1 reporter genes. In human hepatoma HepG2 cells, in contrast with LS174T cells, 1,25-VD3 activated the ABCB1 transcription only in the presence of ectopically expressed VDR. These results suggest that the NR1I subfamily members regulate the ABCB1 expression sharing the binding sites within NURREM and that the physiologically produced LCA and 1,25-VD3 may modulate the ABCB1 expression in human intestines, possibly associated with interindividual variations of ABCB1 expression.
Footnotes
-
This work was supported in part by the Ministry of Education, Culture, Sports, Sciences and Technology of Japan; the Ministry of Health, Labor, and Welfare of Japan; and the Comprehensive Research and Education Center for Planning of Drug Development and Clinical Education, Tohoku University 21st Century “Center of Excellence” Program.
-
This work was presented in part as follows: Tachibana S, Ohya M, Toriyabe T, Nagata K, Yoshinari K, and Yamazoe Y (2007) Induction of intestinal MDR1 by 1α,25-dihydroxyvitamin D3, a vitamin D receptor ligand. 8th International Meeting of the International Society for the Study of Xenobiotics; 2007 Oct 9–12; Sendai, Japan. International Society for the Study of Xenobiotics (ISSX), Washington, DC.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.109.027219.
-
ABBREVIATIONS: PXR, pregnane X receptor; RXR, retinoid X receptor; kb, kilobase(s); CAR, constitutive androstane receptor; DR4, direct repeat separated by four bases; VDR, vitamin D receptor; 1,25-VD3, 1α,25-dihydroxyvitamin D3; LCA, lithocholic acid; VDRE, vitamin D receptor-responsive element; ER6, everted repeat separated by six bases; DR3, direct repeat separated by three bases; DMSO, dimethyl sulfoxide; PCR, polymerase chain reaction; GAPDH, glyceraldehyde-3-phophate dehydrogenase; SEAP, secreted alkaline phosphatase; TK, thymidine kinase; siRNA, small interfering RNA; NURREM, nuclear receptor-responsive module; FXR, farnesoid X receptor.
-
↵1 Current affiliation: Tohoku Pharmaceutical University, Sendai, Japan.
- Accepted May 21, 2009.
- Received February 18, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|